Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms Journal Article


Authors: Sissung, T. M.; Peer, C. J.; Korde, N.; Mailankody, S.; Kazandjian, D.; Venzon, D. J.; Landgren, O.; Figg, W. D.
Article Title: Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms
Abstract: The combination of carfilzomib, lenalidomide, and dexamethasone (CRd) has induced deep responses in patients with newly diagnosed multiple myeloma. While vascular endothelial growth factor (VEGF) pathway polymorphisms have been associated with clinical outcomes for antiangiogenesis agents, we explored associations between such polymorphisms and CRd clinical response. The VEGF-1498C>T (rs833061) and VEGFR2 V297I (rs2305948) were associated with CRd response (OR ≤ 0.10, P ≤ 0.009), whereas VEGF-1498C>T and VEGFR2 Q472H (rs1870377) were associated with minimum residual disease negativity (P ≤ 0.023). As these SNPs were not associated with disease parameters (e.g., plasma VEGF, albumin, or beta-2-microglobin concentration), data suggest these SNPs may be markers of CRd response. © 2017, Springer-Verlag Berlin Heidelberg (outside the USA).
Keywords: vasculotropin; cancer survival; clinical article; controlled study; protein expression; treatment outcome; vascular endothelial growth factor a; single nucleotide polymorphism; genetics; polymorphism, single nucleotide; lenalidomide; thalidomide; angiogenesis inhibitor; cancer combination chemotherapy; unspecified side effect; cancer patient; comparative study; antineoplastic agent; protein blood level; progression free survival; multiple cycle treatment; multiple myeloma; antineoplastic combined chemotherapy protocols; genetic association; genotype; gene frequency; dexamethasone; pathology; vasculotropin receptor 2; vascular endothelial growth factor receptor-2; heterozygote; albumin; dna; minimal residual disease; drug response; vascular endothelial growth factor; vasculotropin a; drug clearance; beta 2 microglobulin; pharmacogenetics; angiogenesis inhibitors; oligopeptides; dna extraction; carfilzomib; polymorphism; oligopeptide; drug disposition; albumin blood level; vascular endothelial growth factor receptor; kdr; humans; human; priority journal; article; analogs and derivatives; isoetarine
Journal Title: Cancer Chemotherapy and Pharmacology
Volume: 80
Issue: 1
ISSN: 0344-5704
Publisher: Springer  
Date Published: 2017-07-01
Start Page: 217
End Page: 221
Language: English
DOI: 10.1007/s00280-017-3323-8
PUBMED: 28488026
PROVIDER: scopus
PMCID: PMC6387687
DOI/URL:
Notes: Article -- Export Date: 1 August 2017 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Carl Ola Landgren
    334 Landgren
  2. Neha Sanat Korde
    181 Korde